Overview
- A confidential distributor letter from Sun Pharma Distributors Ltd dated July 17 instructed channels to stop distribution and withdraw listed ophthalmic products from the market.
- Reports list specific names such as Depopred, Brinolar, several Lotepred formulations and Nepalact variants, with outlets reporting either 10 or 11 affected products.
- Distributors were told to cease billing immediately and return any stock on priority, and Sun Pharma says its teams are working to restore availability.
- Eye-care experts warned that many of the withdrawn drops are used for post-operative care and chronic conditions like glaucoma and infections, and they urged patients to consult their ophthalmologist rather than stop treatment on their own.
- Public reports give no technical details about the alleged contamination, no batch numbers or regulator-ordered recall have been published, and the withdrawal highlights the critical need for sterile manufacturing of eye medicines and the risk of supply disruption for patients.